Amer Zeidan, MBBS, MHS, on the Phase III IMerge Trial
Cecilia BrownMeeting News | June 2, 2023
Amer Zeidan, MBBS, MHS, of Yale University, discusses results of the phase III IMerge trial, which he presented during the 2023 American Society of Clinical Oncology Annual Meeting. The randomized, double-blind, placebo-controlled study evaluated imetelstat in patients with heavily transfusion dependent non-del(5q) lower-risk myelodysplastic syndromes who relapsed or were refractory to erythropoiesis stimulating agents. ...
Advertisement
Advertisement

Advertisement
Advertisement
Editorial Board

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Trending on MashupMD